Safety Alerts for Human Medical Products > Angiotensin Receptor Blockers (ARBs): Drug Safety Communication - Drug Safety Review Completed

Angiotensin Receptor Blockers (ARBs): Drug Safety Communication - Drug Safety Review Completed

[UPDATED 06/02/2011] FDA’s meta-analysis of 31 randomized controlled trials comparing ARBs to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients receiving ARBs.

Read the MedWatch safety alert, including a link to the Drug Safety Communication, at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm219185.htm


open here please:
Safety Alerts for Human Medical Products > Angiotensin Receptor Blockers (ARBs): Drug Safety Communication - Drug Safety Review Completed